Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
30 hedge funds and large institutions have $6.75M invested in Evoke Pharma in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
85% more call options, than puts
Call options by funds: $703K | Put options by funds: $381K
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
20% more funds holding
Funds holding: 25 → 30 (+5)
0.02% more ownership
Funds ownership: 0.05% → 0.07% (+0.02%)
23% less capital invested
Capital invested by funds: $8.74M → $6.75M (-$1.99M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.47M |
| 2 |
Renaissance Technologies
New York
|
+$591K |
| 3 |
Two Sigma Advisers
New York
|
+$155K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$153K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$101K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$81.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$29.9K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$21.6K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$13.4K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$8.25K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Federated Hermes
Pittsburgh,
Pennsylvania
| $3K | +$1.55K | +3 | +60% |
|
27
Citigroup
New York
| $1K | – | – | – |
|
28
Osaic Holdings
Scottsdale,
Arizona
| $1K | – | – | – |
|
29
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $1K | +$1.55K | +3 | New |
|
|
OSAM
30
O'Shaughnessy Asset Management
Stamford,
Connecticut
| $1K | +$2.06K | +4 | New |
|
|
31
Citadel Advisors
Miami,
Florida
| – | -$81.9K | -159 | Closed |
|
|
DWA
32
Dorsey Wright & Associates
Pasadena,
California
| – | -$8K | -11 | Closed |
|
EVOK Hedge Fund Activity: Q4 2020 in Review
30 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q4 2020, worth a combined $6.75M — down 23% from $8.74M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new EVOK positions and 2 closed out — a net gain of 5 holders — while 9 added to existing stakes and 5 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.47M. The largest seller was Citadel Advisors, exiting entirely with an estimated $81.9K sold.
- 30 institutional investors held Evoke Pharma (EVOK) as of Q4 2020, up from 25 in Q3 2020.
- Funds reported $6.75M of Evoke Pharma stock for Q4 2020, down 23% quarter-over-quarter.
- 7 funds opened new Evoke Pharma positions in Q4 2020 and 2 closed out, a net change of +5 holders.
- The largest Evoke Pharma buyer in Q4 2020 was Morgan Stanley, an estimated $1.47M added.
- The largest Evoke Pharma seller in Q4 2020 was Citadel Advisors, an estimated $81.9K sold.
Based on aggregated 13F filings for Q4 2020.